<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Aims-<z:mp ids='MP_0003674'>Oxidative stress</z:mp> and <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> dysfunction participate together in the development of <z:hpo ids='HP_0001635'>heart failure</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain><z:chebi fb="2" ids="33699">mRNA</z:chebi> levels of <z:chebi fb="3" ids="25375">monoamine</z:chebi> oxidase-A (MAO-A), a <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> enzyme that produces <z:chebi fb="0" ids="30492">H2O2</z:chebi>, increase in several models of <z:hpo ids='HP_0001638'>cardiomyopathies</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Therefore, we hypothesized that an increase in cardiac MAO-A could cause cardiac <z:mp ids='MP_0003674'>oxidative stress</z:mp> and <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> damage, leading to cardiac dysfunction </plain></SENT>
<SENT sid="3" pm="."><plain>In the present study, we evaluated the consequences of cardiac MAO-A augmentation on <z:hpo ids='HP_0011010'>chronic</z:hpo> oxidative damage, cardiomyocyte survival and heart function, and identified the intracellular pathways involved </plain></SENT>
<SENT sid="4" pm="."><plain>Results-We generated transgenic mice (Tg) with cardiac-specific MAO-A overexpression </plain></SENT>
<SENT sid="5" pm="."><plain>Transgenic mice displayed cardiac MAO-A activity levels similar to those found in <z:hpo ids='HP_0001635'>heart failure</z:hpo> and aging </plain></SENT>
<SENT sid="6" pm="."><plain>As expected, Tg mice showed a significant decrease in the cardiac amounts of the MAO-A substrates <z:chebi fb="19" ids="28790">serotonin</z:chebi> and <z:chebi fb="15" ids="33569">noradrenaline</z:chebi> </plain></SENT>
<SENT sid="7" pm="."><plain>This was associated with enhanced <z:chebi fb="0" ids="30492">H2O2</z:chebi> generation in situ and <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> DNA oxidation </plain></SENT>
<SENT sid="8" pm="."><plain>As a consequence, MAO-A Tg mice demonstrated progressive loss of cardiomyocytes by <z:mp ids='MP_0001651'>necrosis</z:mp> and <z:e sem="disease" ids="C0849925" disease_type="Disease or Syndrome" abbrv="">ventricular failure</z:e>, which were prevented by <z:hpo ids='HP_0011010'>chronic</z:hpo> treatment with the MAO-A inhibitor clorgyline and the anti-oxidant N-<z:chebi fb="9" ids="46887">acetyl</z:chebi>-<z:chebi fb="0" ids="15356">cystein</z:chebi> </plain></SENT>
<SENT sid="9" pm="."><plain>Interestingly, Tg hearts exhibited p53 accumulation and down-regulation of <z:chebi fb="6" ids="26336">PGC</z:chebi>-1α, a master regulator of <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> function </plain></SENT>
<SENT sid="10" pm="."><plain>This was concomitant with cardiac <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> ultrastructural defects and ATP <z:mpath ids='MPATH_63'>depletion</z:mpath> </plain></SENT>
<SENT sid="11" pm="."><plain>In vitro, MAO-A adenovirus transduction of neonatal cardiomyocytes mimicked the results in MAO-A Tg mice, triggering <z:mp ids='MP_0003674'>oxidative stress</z:mp>-dependent p53 activation, leading to <z:chebi fb="6" ids="26336">PGC</z:chebi>-1α down-regulation, <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> impairment and <z:mp ids='MP_0010632'>cardiomyocyte necrosis</z:mp> </plain></SENT>
<SENT sid="12" pm="."><plain>Innovation and conclusion-We provide the first evidence that MAO-A upregulation in the heart causes oxidative <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> damage, p53-dependent repression of <z:chebi fb="6" ids="26336">PGC</z:chebi>-1α <z:mp ids='MP_0010632'>cardiomyocyte necrosis</z:mp> and <z:hpo ids='HP_0011010'>chronic</z:hpo> ventricular dysfunction </plain></SENT>
</text></document>